South Korea Car-T Cell Therapy Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
South Korea Car-T Cell Therapy Market is Segmented By Targeted Antigen (CD19, CD20, BCMA, GCP-3, Claudin 18.2), By Therapeutic Application (B-cell non-Hodgkin\'s lymphoma, Multiple Myeloma, Cervical Cancer, Gastric Cancer, Lung Cancer, Others). The report offers the value (in USD Million) for the above-mentioned segments
Competitive overview of South Korea Car-T Cell Therapy Market
The major players operating in the South Korea Car-T Cell Therapy Market include Novartis AG, Pfizer, Inc., Bristol Myers Squibb, CARsgen Therapeutics Co., Ltd., Fate Therapeutics, Inc., Poseida Therapeutics, Inc., Eureka Therapeutics, Inc., Johnson & Johnson, Cellular Biomedicine Group, and Gilead Sciences, Inc.
South Korea Car-T Cell Therapy Market Leaders
- Novartis AG
- Pfizer, Inc.
- Bristol Myers Squibb
- CARsgen Therapeutics Co., Ltd.
- Fate Therapeutics, Inc.
*Disclaimer: Major players are listed in no particular order.
South Korea Car-T Cell Therapy Market - Competitive Rivalry, 2023
South Korea Car-T Cell Therapy Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights